Author:
Nailwal Namrata P., ,Doshi Gaurav M.
Abstract
The present study was conducted on timolol maleate (a non-selective beta-blocker) using in vitro assays and in vivo models of rats. It was tested for its anti-inflammatory activity at three dose levels (1.028 mg kg-1 , 5.14 mg kg -1 and 10.28 mg kg -1). Furthermore, the investigation was supported by the estimation of tumor necrosis factor-alpha (tNF-α), interleukin-1 (IL- 1) and histopathological examination. It was observed that at 1.028 mg kg -1, 5.14 mg kg -1 and 10.28 mg kg -1 the drug showed anti-inflammatory activities. moreover, plasma levels of tNF-α and IL-1 showed inhibition. Histopathological examination confirmed the highest anti-inflammatory activity at 5.14 mg kg -1. Thus, the conducted studies revealed that timolol maleate, when given orally does possesses an anti-inflammatory potential.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference25 articles.
1. Ferrero-Miliani L., Nielsen O.H., Andersen P.S. and Girardin S.E.: Chronic inflammation: the importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol., 2007, 147(2), 227-235.
2. 2. Libby P.: Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr. Rev., 2007, 65(12 Pt 2), S140-146.
3. 3. Abdulkhaleq L.A., Assi M.A., Abdullah R., Zamri-Saad M., Taufiq-Yap Y.H. and Hezmee M.N.M.: The crucial roles of inflammatory mediators in inflammation: A review. Vet World, 2018, 11(5), 627-635.
4. 4. Vogel H. G.: Drug discovery and evaluation. Pharmacological assays , Springer Berlin, Heidelberg, 2008, pp.983-1116.
5. 5. Patel M. and Gowda S.: In vivo animal models in preclinical evaluation of anti-inflammatory activity-A Review. IJPRAS., 2012, 1 (2), 01-05.